Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

SELLAS Life Sciences Group, Inc. (SLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.29-0.45 (-6.68%)
At close: 04:00PM EST
6.22 -0.07 (-1.07%)
After hours: 05:30PM EST
Advertisement
Sign in to post a message.
  • R
    Real Immuno Investor 10
    Her 2 Phase 2B Trial results Imminent - virtually identical to Data that Launched glsi 2,000%. Co Twitter and Linkdin accounts activated - “stay tuned”. Best Investment opportunity in the whole market right here right now.
    Bullish
  • R
    Real Immuno Investor 10
    Dr Mittendorf ran the GLSI trial and Says Nps is better than the GLSI Drug - Glsi Market Cap $415M
    SLS Market Cap $100? Nps Results Imminent ie. any day now
    Oversold --- AML Phase 3 FDA worth billions in 6 months! Shorts porkered themselves way down here!
    Bullish
  • j
    james
    Chairman of the Leukemia Dept at the University of Texas MD Anderson Cancer Center - “Given these results, (21 months of Survival vs 5 with Best available treatment) it is particularly exciting to be involved in the ongoing pivotal Phase 3 REGAL study of GPS in AML patients in CR2 said Hagop M. Kan.tarjian, MD, REGALs principal investigator. We are working to rapidly enroll patients who meet entry criteria for this study and believe these compelling results will enhance the visibility of this novel therapy and encourage broader participation in the pivotal Phase 3 trial."

    Hard to know the truth seeing as how dman keeps saying this is a scam
    Bullish
  • j
    james
    When all the scammers posting about SLS being a scam keep in mind, the Chairman of MD Anderson’s Leukemia Dept, a guy with 20 FDA approvals, said this:- “Given these results, (21 months of Survival vs 5 with Best available treatment) it is particularly exciting to be involved in the ongoing pivotal Phase 3 REGAL study of GPS in AML patients in CR2 said Hagop M. Kan.tarjian, MD, REGALs principal investigator. We are working to rapidly enroll patients who meet entry criteria for this study and believe these compelling results will enhance the visibility of this novel therapy and encourage broader participation in the pivotal Phase 3 trial."
    Bullish
  • R
    Real Immuno Investor 10
    https://clinicaltrials.gov/ct2/show/NCT02297698 ‘Estimation primary completion date is December 2021’
    Results Imminent -- Nps better than Glsi drug $29 $49 possible from Dr Mittendorf/ Peoples Glsi Trial Docs “Trastuzumab increased the sensitivity of the tumor cells to CTL-mediated lysis after stimulation with either nelipepimut-S or GP2, even in patients with low levels of HER2 expression. Interestingly, they also found peripheral blood lymphocytes lyse trastuzumab-treated breast cancer cells more efficiently after nelipepimut-S vaccination. We are currently investigating the possibility of a synergistic immunologic effect when nelipepimut-S is given in combination with trastuzumab in a phase II trial in HER2 over-expressing (3+ by IHC; NCT02297698).’
    The website https://clinicaltrials.gov/ct2/show/NCT02297698 says ‘Estimation primary completion date is December 2021’
    I see now that during the SABC Symposium 2021 (7-10 Dec 2021), there is a Spotlight Session https://www.sabcs.org/Program/Daily-Schedule/Day-3
    Poster Session 4 Hall 1 (from 5.00 to 6.30 PM)
    Where Mittendorf will attend to discuss ‘Spotlight Poster Discussion 10 - Novel Immunotherapy Approaches’
    Bullish
  • d
    david
    Its best to be real investors in this market now. Do ur research and see if it matches what big money is doing.
  • D
    Dangremaus
    This is puzzling price action. The long-term investors have done their DD and know where we're going. Who would honestly be selling at this point? Is it really selling or just short-selling? I'm curious because with only 15.8M outstanding shares, there are bound to be many long-term investors here. How many weak hands are there? Nothing has fundamentally changed with the company--we're still on target. I do agree that 2000% gains are worth waiting for in light of a 50-75% loss in the past 6 months.
  • B
    Brandon
    Okay November is in the books. Another month of data to record. Only a matter of time Angelos comes through with any kind of announcements. He has, I would say two weeks to announce something good than it gets to close to the holidays and will have to wait till beginning of January. NPS trial should be very positive!
  • L
    Lars
    So please tell me...if you are awaiting bad news....why do you get yourself a Twitter account?
    I would guess it is a way to assure everyone but those watching the news update on the homepage and invited web casts gets the news simultaneously. Which probably also is liked by the rules of the stock market.
    I don't see that the news will be first public in conferences or poster sessions while these normally requires that that info is sent in advanced.
  • C
    Cured
    Another Phase 3 gets halted or Efficacy - A likely possibility for Gps Phase 3 AML
    https://www.curetoday.com/view/melanoma-treatment-results-were-so-good-researchers-ended-the-trial
    Bullish
  • R
    Real Immuno Investor 10
    Results Imminent Nps better than Glsi drug $29 49 possible from Dr Mittendorf/ Peoples Glsi Trial Docs “Trastuzumab increased the sensitivity of the tumor cells to CTL-mediated lysis after stimulation with either nelipepimut-S or GP2, even in patients with low levels of HER2 expression. Interestingly, they also found peripheral blood lymphocytes lyse trastuzumab-treated breast cancer cells more efficiently after nelipepimut-S vaccination. We are currently investigating the possibility of a synergistic immunologic effect when nelipepimut-S is given in combination with trastuzumab in a phase II trial in HER2 over-expressing (3+ by IHC; NCT02297698).’
    The website https://clinicaltrials.gov/ct2/show/NCT02297698 says ‘Estimation primary completion date is December 2021’
    I see now that during the SABC Symposium 2021 (7-10 Dec 2021), there is a Spotlight Session https://www.sabcs.org/Program/Daily-Schedule/Day-3
    Poster Session 4 Hall 1 (from 5.00 to 6.30 PM)
    Where Mittendorf will attend to discuss ‘Spotlight Poster Discussion 10 - Novel Immunotherapy Approaches’
    Bullish
  • E
    Ez$
    When time is money, is 6 months a long time to wait for 1,000 5,000% gains? Cpxx got bought for 1.5B when they published phase 3 data. EZ$
    Bullish
  • B
    Brandon
    Wall Street has no confidence in Angelos. He has closed no significant deals or partnerships since he took over the company. He allows Maxim and it’s criminal short friends to manipulate the stock. You took our only phase 3 trial and you added an entire year on it. Remember originally news was end of this year. I am wondering if you were going to screw up and NPS?
  • s
    sWINger
    I don't want to be kicking myself for not buying more down here. Nps trial info followed by the license deal in December. Jan for the Keytruda Ovarian Cancer data 18 months for an advanced patient setting with 9 months of median OS Jan/Feb Opdivo Mesothelioma results - potential miracle cure for a sarcomatoid patient.
    and then only 7 months from a billion dollar FDA AML review
  • k
    kC
    Now there is NO volume for all the Lowlife to COVER -- all time high of 70% sold Short Monday and 50% sold Short Tuesday - only reason sls was down. Holders aren't selling. They need our shares, look at all the short desperate posts trying to convince us its the co when it is SHORT selling to manipulate the price before huge news, over due News. Do not Get Short Conned.
    Bullish
  • E
    Ez$
    $SLS Market Cap 100.068M
    Gps Phase 3 AML data 7 months from now that will be worth $3-5B
    $jazz bought $cpxx when they published Phase 3 Aml data -- that was 1/4 as good as Gps was in Phase 2
    After holiday weekend rumors, Jazz confirms $1.5B buyout of tiny Celator
    The Wall Street Journal kicked off rumors over the Memorial Day weekend that Ireland’s Jazz Pharmaceuticals was set to buy Celator, and early this morning the two confirmed the $1.5 billion deal was t...
    https://www.fiercebiotech.com/biotech/after-holiday-weekend-rumors-jazz-confirms-1-5b-buyout-tiny-celator

    All the following have partnership or industry comps $JAZZ $XBI
    3 Trial Results coming in DEC and JAN $BMY $RHHBY $MRK
    Bullish
  • D
    Dangremaus
    Anyone selling right now is selling at a loss. I don’t feel bad for them. I highly doubt the short interest is going up—it’s simply impatient retail investors.
  • D
    D
    Does anyone else remember Angelos telling investors 2021 would be a great year?
  • S
    Stephens
    Great buying time for the smart money
    Bullish
Advertisement
Advertisement